7Baggers

Viking Therapeutics, Inc
(NASDAQ:VKTX) 

VKTX stock logo

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TR), ...

Founded: 2012
Full Time Employees: 17
Sector: Healthcare
Industry: Biotechnology
Pharmaceuticals
Share this website to your friends
• Market Cap:
• Exchange:
• Shs Outstanding:
• Employees:
• Beta:
• Return on Equity (ROE) ttm:
• Return on Assets (ROA) ttm:
• EPS ttm:
• Book value per Share:
• Cash per Share:
• Current ast per Share:
• P/E ttm:
• P/E forward:
• P/E ttm high:
• P/E ttm low:
• P/S ttm:
• P/B ttm:
• P/FCF ttm:
• PEG ratio:
• Cash Ratio ttm:
• Quick Ratio ttm:
• Current Ratio ttm:
• Gross Mgn ttm:
• EBITDA Mgn ttm:
• Operating Mgn ttm:
• Net Income Mgn ttm:
• Trailing Div yield:
• Forward Div yield:
• Payout Ratio ttm:
• Ex-Dividend date:
• Target Price High:
• Target Price Low:
• Target Price Mean:
• Number of Analysts:
• Debt Ratio ttm:
• Debt to Equity ttm:
• Total Net Debt:
At a glance:
Bull Thesis:
Bear Thesis:
Main Competitors:
Moat:
Income Statements:
Quarterly
Annual
    Unit: USD2026-03-31 2025-12-31 2025-09-30 2025-06-30 2025-03-31 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2020-06-30 2020-03-31 2019-12-31 2019-09-30 2019-06-30 2019-03-31 2018-12-31 2018-09-30 2018-06-30 2018-03-31 2017-12-31 2017-09-30 2017-06-30 2017-03-31 2016-12-31 2016-09-30 2016-06-30 2016-03-31 2015-12-31 2015-09-30 2015-06-30 2015-03-31 
                                                 
      revenues
    		                                             
      operating expenses:
    		                                             
      research and development
    		150,150,000 153,459,000 89,953,000 60,153,000 41,391,000 30,987,000 22,785,000 23,769,000 24,103,000 20,502,000 18,379,000 13,917,000 11,008,000 16,178,000 11,959,000 13,542,000 12,555,000 9,847,000 10,795,000 12,804,000 11,535,000 9,049,000 7,116,000 7,780,000 7,987,000 6,451,000 5,279,000 7,333,000 4,496,000 5,089,000 5,687,000 5,221,000 3,043,000 3,033,017 3,464,639 3,715,379 3,528,150 2,647,469 2,104,794 2,371,058 1,877,178 3,219,414 2,507,553 1,100,906 138,969 
      general and administrative
    		13,975,000 11,279,000 8,608,000 14,421,000 14,078,000 15,251,000 13,771,000 10,285,000 9,970,000 8,783,000 8,886,000 9,823,000 9,529,000 4,105,000 4,237,000 4,089,000 3,690,000 2,663,000 2,608,000 2,737,000 2,693,000 2,217,000 2,727,000 2,826,000 2,961,000 2,422,000 2,160,000 2,236,000 2,310,000 1,948,000 1,707,000 1,704,000 1,762,000 1,394,235 1,226,892 1,267,364 1,440,512 1,090,055 1,159,488 1,206,995 1,390,239 1,400,889 1,780,668 1,526,008 322,071 
      total operating expenses
    		164,125,000 164,738,000 98,561,000 74,574,000 55,469,000 46,238,000 36,556,000 34,054,000 34,073,000 29,285,000 27,265,000 23,740,000 20,537,000 20,283,000 16,196,000 17,631,000 16,245,000 12,510,000 13,403,000 15,541,000 14,228,000 11,266,000 9,843,000 10,606,000 10,948,000 8,873,000 7,439,000 9,569,000 6,806,000 7,037,000 7,394,000 6,925,000 4,805,000 4,427,252 4,691,531 4,982,743 4,968,662 3,737,524 3,264,282 3,578,053 3,267,417 4,620,303 4,288,221 2,626,914 461,040 
      income from operations
    		-164,125,000 -164,738,000 -98,561,000 -74,574,000 -55,469,000 -46,238,000 -36,556,000 -34,054,000 -34,073,000 -29,285,000 -27,265,000 -23,740,000 -20,537,000 -20,283,000 -16,196,000 -17,631,000 -16,245,000 -12,510,000 -13,403,000 -15,541,000 -14,228,000 -11,266,000 -9,843,000 -10,606,000 -10,948,000 -8,873,000 -7,439,000 -9,569,000 -6,806,000 -7,037,000 -7,394,000 -6,925,000 -4,805,000 -4,427,252 -4,691,531 -4,982,743 -4,968,662 -3,737,524 -3,264,282 -3,578,053 -3,267,417 -4,620,303 -4,288,221 -2,626,914 -461,040 
      yoy
    		195.89% 256.28% 169.62% 118.99% 62.79% 57.89% 34.08% 43.45% 65.91% 44.38% 68.34% 34.65% 26.42% 62.13% 20.84% 13.45% 14.18% 11.04% 36.17% 46.53% 29.96% 26.97% 32.32% 10.84% 60.86% 26.09% 0.61% 38.18% 41.64% 58.95% 57.60% 38.98% -3.29% 18.45% 43.72% 39.26% 52.07% -19.11% -23.88% 36.21% 608.71%     
      qoq
    		-0.37% 67.14% 32.17% 34.44% 19.96% 26.49% 7.35% -0.06% 16.35% 7.41% 14.85% 15.60% 1.25% 25.23% -8.14% 8.53% 29.86% -6.66% -13.76% 9.23% 26.29% 14.46% -7.19% -3.12% 23.39% 19.28% -22.26% 40.60% -3.28% -4.83% 6.77% 44.12% 8.53% -5.63% -5.84% 0.28% 32.94% 14.50% -8.77% 9.51% -29.28% 7.74% 63.24% 469.78%  
      other income:
    		                                             
      amortization of financing costs
    		  -8,000 -24,000 -24,000 -24,000 -24,000 -18,000 -28,000 -26,000 -2,000 -32,000 -28,000 -8,000 -27,000 -12,000 -12,000 -12,000 35,000 -21,000 -21,000 -21,000 -20,000 -20,000 -45,000 -46,000 -40,000 -30,000 -30,000 -30,000 -30,000 -30,000 -30,000 -33,516 -17,568 -421,781 -98,179 -92,849 -45,852       
      interest income
    		5,800,000 7,035,000 7,772,000 9,033,000 9,864,000 10,844,000 11,531,000 11,820,000 6,745,000 4,706,000 4,733,000 4,547,000 1,034,000 732,000 450,000 253,000 154,000 159,000 125,000 181,000 239,000 313,000 576,000 1,040,000 1,304,000 1,469,000 1,742,000 1,925,000 1,914,000 1,839,000 824,000 392,000 181,000 1,819 2,111           
      total other income
    		5,800,000 7,076,000 7,774,000 9,013,000 9,840,000 10,821,000 11,616,000 11,804,000 6,717,000 4,680,000 4,731,000 4,515,000 1,006,000 724,000 423,000 199,000 142,000 154,000 160,000 160,000 218,000 318,000 555,000 1,034,000 1,261,000 1,423,000 1,708,000 1,895,000 1,882,000 1,797,000 794,000 253,000 1,254,000 342,779 -1,408,127 -188,891 -253,238 92,915 -543,149 -114,740 -319,571 -470,660 -448,323   
      net income
    		-158,325,000 -157,662,000 -90,787,000 -65,561,000 -45,629,000 -35,417,000 -24,940,000 -22,250,000 -27,356,000 -24,605,000 -22,534,000 -19,225,000 -19,531,000 -19,559,000 -15,773,000 -17,432,000 -16,103,000 -12,356,000 -13,243,000 -15,381,000 -14,010,000 -10,948,000 -9,288,000 -9,572,000 -9,687,000 -7,450,000 -5,731,000 -7,674,000 -4,924,000 -5,240,000 -6,600,000 -6,672,000 -3,551,000 -4,084,473 -6,099,658 -5,171,634 -5,221,900 -3,644,609 -3,807,431 -3,692,793 -3,586,988 -5,090,963 -4,736,544 -7,865,066 -5,711,415 
      yoy
    		246.98% 345.16% 264.02% 194.66% 66.80% 43.94% 10.68% 15.73% 40.06% 25.80% 42.86% 10.29% 21.29% 58.30% 19.10% 13.33% 14.94% 12.86% 42.58% 60.69% 44.63% 46.95% 62.07% 24.73% 96.73% 42.18% -13.17% 15.02% 38.67% 28.29% 8.20% 29.01% -32.00% 12.07% 60.20% 40.05% 45.58% -28.41% -19.62% -53.05% -37.20%     
      qoq
    		0.42% 73.66% 38.48% 43.68% 28.83% 42.01% 12.09% -18.67% 11.18% 9.19% 17.21% -1.57% -0.14% 24.00% -9.52% 8.25% 30.33% -6.70% -13.90% 9.79% 27.97% 17.87% -2.97% -1.19% 30.03% 29.99% -25.32% 55.85% -6.03% -20.61% -1.08% 87.89% -13.06% -33.04% 17.94% -0.96% 43.28% -4.28% 3.10% 2.95% -29.54% 7.48% -39.78% 37.71%  
      other comprehensive loss, net of tax:
    		                                             
      unrealized gain on securities
    		-1,250,000 -10,000 540,000 26,000 563,000 -2,252,000 3,902,000 -699,000 -1,125,000 437,000 221,000 -417,000 501,000 -203,250 111,000   -29,000 19,000 -85,000  -8,000 -379,000 1,145,000 -824,000 -145,000 -82,000 288,000 374,000 -24,250 30,000 -38,000  -16,211 2,442 1,500 -607 -755 649 -6,591 7,175 -2,522 7,613   
      foreign currency translation gain
    		16,000 14,000  24,000  -14,500 2,000 26,000     -17,000    31,000                             
      comprehensive loss
    		-159,559,000 -157,658,000 -90,247,000 -65,511,000 -45,057,000 -37,837,000 -21,036,000 -22,923,000 -28,566,000 -24,089,000 -22,399,000 -19,647,000 -19,047,000 -18,900,000 -15,885,000 -17,670,000 -16,965,000 -12,735,000 -13,224,000 -15,466,000 -14,060,000 -10,956,000 -9,667,000 -8,427,000 -10,511,000 -7,595,000 -5,813,000 -7,386,000 -4,550,000 -5,546,000 -6,570,000 -6,710,000 -3,640,000 -4,100,684 -6,097,216 -5,170,134 -5,222,507 -3,645,364 -3,806,782 -3,699,384 -3,579,813 -5,093,485 -4,728,931 -7,877,527  
      basic and diluted net loss per share
    		-1.37 -1.39 -0.81 -0.58 -0.41 -0.32 -0.22 -0.2 -0.26 -0.25 -0.23 -0.19 -0.25                     -0.12 -0.22 -0.21 -0.23 -0.16 -0.2 -0.22 -0.4 -0.99 -0.53 -1.07 -1.4 
      weighted-average shares used for eps calculation
    		115,568 112,667 112,320 112,134 112,069 109,037 110,911 110,390 103,457 94,347 99,846 99,010 78,352 76,834 76,505,000 76,842,000 77,413,000 77,198 78,009,000 77,897,000 74,782,000 72,597 72,643,000 72,487,000 72,356,000 71,959 72,040,000 71,921,000  57,580 61,232,000 52,767,000  25,978,098 27,469,784 24,118,887 22,352,921 16,278,292 18,991,971 17,105,374 9,015,778 6,355,869 8,947,480 7,331,861 4,073,609 
      realized gain on investments
    		 41,000 10,000 4,000  1,000 109,000 2,000              26,000 -1,000 14,000 2,000  6,000                   
      foreign currency translation loss
    		    9,000    -85,000 79,000 -86,000 -5,000  141,000 -223,000 -207,000                              
      realized loss on investments
    		               -42,000             -2,000                 
      basic and diluted net loss per common share
    		             -160 -210 -230 -210 -137.5 -170 -200 -190 -97.5 -130 -130 -130 -62.5 -80 -110  -80 -110 -130              
      unrealized loss on securities
    		               -31,000 -893,000    -50,000            -89,000           -12,461  
      other comprehensive gain, net of tax:
    		                                             
      change in fair value of debt conversion feature liability
    		                               37,000 1,361,000 632,628 -1,136,074 570,676 277,698 620,087 -64,514 412,050 96,547 -216,841 -197,496 546,485 82,656 
      amortization of debt discount
    		                               -146,000 -258,000 -258,152 -256,596 -336,656 -431,227 -431,227 -431,227 -524,977 -400,657 -240,516 -240,515 240,515 171,955 
      net loss per common share
    		                                             
      basic
    		                            -70    -80             
      diluted
    		                            -70    -100             
      weighted-average shares used for eps calculation
    		115,568 112,667 112,320 112,134 112,069 109,037 110,911 110,390 103,457 94,347 99,846 99,010 78,352 76,834 76,505,000 76,842,000 77,413,000 77,198 78,009,000 77,897,000 74,782,000 72,597 72,643,000 72,487,000 72,356,000 71,959 72,040,000 71,921,000  57,580 61,232,000 52,767,000  25,978,098 27,469,784 24,118,887 22,352,921 16,278,292 18,991,971 17,105,374 9,015,778 6,355,869 8,947,480 7,331,861 4,073,609 
      basic
    		                            71,755,000    44,649,000             
      diluted
    		                            71,755,000    45,306,000             
      interest expense
    		                                   -1,130 -1,530 -3,096 -1,556 -1,813 -15,461 -13,303 -10,312 29,814 35,253 
      change in fair value of accrued license fees
    		                                           4,421,338 4,960,511 
      other expenses:
    		                                             
      total other expenses
    		                                           5,238,152 5,250,375 
    Balance Sheets:
    Quarterly
    Annual
      Unit: USD2026-03-31 2025-12-31 2025-09-30 2025-06-30 2025-03-31 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2020-06-30 2020-03-31 2019-12-31 2019-09-30 2019-06-30 2019-03-31 2018-12-31 2018-09-30 2018-06-30 2018-03-31 2017-12-31 2017-09-30 2017-06-30 2017-03-31 2016-12-31 2016-09-30 2016-06-30 2016-03-31 2015-12-31 2015-09-30 2015-06-30 2015-03-31 
                                                   
        assets
      		                                             
        current assets:
      		                                             
        cash and cash equivalents
      		118,116,000 165,810,000 100,376,000 33,880,000 37,940,000 26,676,000 50,347,000 43,915,000 195,579,000 55,516,000 37,185,000 69,519,000 18,362,000 36,632,000 29,408,000 16,226,000 12,454,000 26,371,000 11,264,000 8,829,000 16,805,000 29,117,000 3,870,000 18,790,000 15,260,000 8,377,000 30,952,000 19,123,000 14,343,000 24,779,000 169,506,000 34,610,000 36,356,000 8,988,478 2,568,063 3,393,651 4,359,046 3,075,502 3,054,892 5,159,930 3,958,763 768,550 2,140,115 9,497,200  
        short-term investments – available-for-sale
      		484,848,000 539,929,000 614,194,000 773,844,000 813,918,000 875,936,000 880,093,000 898,348,000 767,397,000 306,563,000 339,056,000 323,401,000 117,302,000                                 
        prepaid clinical trial and preclinical study costs
      		4,021,000 8,053,000 21,891,000 16,478,000 13,300,000 3,476,000 4,476,000 3,323,000 2,716,000 2,624,000 4,389,000 5,491,000 9,878,000 8,144,000 9,167,000 9,859,000 8,012,000 7,806,000 7,235,000 8,254,000 7,559,000 7,276,000 7,120,000 6,702,000 6,738,000 7,458,000 612,000 343,000 168,000 335,000 1,847,000 1,499,000 1,014,000             
        prepaid expenses and other current assets
      		1,224,000 1,806,000 2,242,000 2,815,000 865,000 1,128,000 1,733,000 138,000 643,000 2,522,000 670,000 960,000 3,926,000 3,411,000 956,000 1,087,000 388,000 619,000 915,000 1,150,000 625,000 442,000 710,000 914,000 547,000 405,000 572,000 665,000 251,000 278,000 607,000 593,000 249,000 388,969 340,121 447,932 177,451 824,269 1,005,471 1,113,696 909,895 1,097,599 1,442,629 610,198 33,391 
        total current assets
      		608,209,000 715,598,000 738,703,000 827,017,000 866,023,000 907,216,000 936,649,000 945,724,000 966,335,000 367,225,000 381,300,000 399,371,000 149,468,000 167,040,000 165,146,000 179,863,000 193,299,000 210,528,000 224,285,000 237,662,000 249,863,000 256,104,000 263,134,000 270,618,000 276,446,000 283,501,000 289,256,000 293,644,000 299,137,000 302,133,000 306,616,000 144,258,000 78,731,000 21,851,798 11,525,074 14,264,002 14,673,917 13,974,829 15,623,313 18,310,165 12,161,521 15,201,648 18,932,251 22,269,649 360,398 
        right-of-use assets
      		 85,000 666,000 780,000 892,000 1,003,000 1,113,000 977,000 1,052,000 1,126,000 1,200,000 1,273,000 1,346,000 1,418,000 1,489,000 1,560,000 1,632,000 25,000 101,000 176,000 249,000 321,000 392,000 462,000 530,000 598,000 664,000 730,000 794,000                 
        deposits
      		33,000 46,000 46,000 46,000 46,000 46,000 46,000 33,000 33,000 33,000 33,000 33,000 33,000 33,000 33,000 33,000 33,000 33,000    29,000 29,000 29,000 29,000 29,000 29,000 29,000 29,000 29,000     39,341 39,341 39,341 39,341 80,000 80,000 80,000 80,000    
        total assets
      		608,242,000 715,729,000 739,415,000 827,851,000 866,993,000 908,321,000 937,888,000 946,839,000 967,518,000 368,490,000 382,663,000 400,693,000 150,895,000 168,529,000 166,683,000 181,508,000 195,028,000 210,662,000 224,474,000 237,845,000 250,139,000 256,502,000 263,623,000 271,198,000 277,104,000 284,256,000 290,122,000 294,493,000 300,080,000 302,312,000 306,796,000 144,468,000 78,971,000 22,121,411 11,839,444 14,320,911 15,152,607 14,535,708 16,317,693 18,549,007 12,756,902 15,439,103 19,012,251 22,269,649 2,769,322 
        liabilities and stockholders’ equity
      		                                             
        current liabilities:
      		                                             
        accounts payable
      		67,183,000 53,251,000 4,413,000 5,494,000 7,702,000 9,813,000 254,000 11,090,000 5,225,000 7,512,000 5,711,000 5,611,000 3,799,000 8,529,000 3,142,000 6,104,000 3,119,000 1,444,000 2,852,000 4,210,000 4,848,000 3,988,000 2,756,000 3,209,000 3,098,000 2,431,000 2,095,000 1,870,000 1,676,000 959,000 1,215,000 1,493,000 658,000 1,529,935 1,555,472 1,304,711 1,726,824 1,203,888 881,311 1,206,384 1,172,351 592,414 401,672 1,008,277 1,879,414 
        other accrued liabilities
      		39,142,000 23,279,000 21,217,000 26,018,000 11,373,000 17,111,000 24,951,000 13,669,000 27,220,000 11,299,000 7,375,000 7,553,000 11,541,000 13,114,000 10,620,000 8,522,000 7,999,000 7,305,000 8,386,000 8,463,000 7,789,000 7,811,000 6,636,000 5,528,000 5,135,000 4,044,000 3,802,000 3,468,000 2,961,000 3,591,000 3,528,000 2,612,000 1,889,000 2,256,543 2,837,392 2,418,355 1,655,342 1,237,122 996,437 852,744 745,774 1,384,398 1,103,432 119,647 517,892 
        lease liability, current
      		 137,000 437,000 468,000 498,000 489,000 480,000 334,000 329,000 324,000 319,000 314,000 309,000 304,000 299,000 238,000 150,000 29,000 115,000 198,000 279,000 330,000 323,000 316,000 309,000 302,000 295,000 288,000 281,000                 
        total current liabilities
      		106,325,000 76,667,000 26,067,000 31,980,000 19,573,000 27,413,000 25,685,000 25,093,000 32,774,000 19,135,000 13,405,000 13,478,000 15,649,000 21,947,000 14,061,000 14,864,000 11,268,000 8,778,000 11,353,000 12,871,000 12,916,000 12,129,000 9,715,000 9,053,000 8,542,000 6,777,000 6,192,000 5,626,000 4,918,000 4,550,000 4,743,000 4,105,000 6,339,000 8,656,575 9,613,483 7,726,978 3,382,166 6,476,534 6,077,692 5,738,892 1,918,125 1,976,812 5,722,551 4,876,110 27,708,696 
        total liabilities
      		106,325,000 76,667,000 26,385,000 32,390,000 20,075,000 28,043,000 26,440,000 25,859,000 33,626,000 20,071,000 14,423,000 14,578,000 16,830,000 23,207,000 15,398,000 16,278,000 12,758,000 8,778,000 11,353,000 12,871,000 12,916,000 12,158,000 9,830,000 9,251,000 8,821,000 7,137,000 6,630,000 6,139,000 5,506,000 4,562,000 4,743,000 4,105,000 6,339,000 8,656,575 9,613,483 7,733,032 7,606,520 6,492,841 6,098,168 5,763,538 6,987,163 6,714,105 5,741,700 4,876,110 30,608,365 
        commitments and contingencies
      		                                             
        stockholders’ equity:
      		                                             
        preferred stock, 0.00001 par value: 10,000,000 shares authorized at march 31, 2026 and december 31, 2025; no shares issued and outstanding at march 31, 2026 and december 31, 2025
      		                                             
        common stock
      		1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 358 285 277 239 208 199 193 97 97 98 98 60 
        additional paid-in capital
      		1,508,643,000 1,486,229,000 1,402,539,000 1,394,723,000 1,380,669,000 1,368,972,000 1,362,305,000 1,350,801,000 1,340,789,000 733,546,000 729,278,000 724,754,000 453,057,000 445,267,000 432,330,000 430,390,000 428,086,000 425,614,000 424,116,000 422,745,000 419,528,000 412,589,000 411,082,000 409,569,000 407,478,000 405,803,000 404,581,000 403,630,000 402,464,000 401,090,000 399,847,000 231,587,000 157,146,000 94,339,179 78,999,693 77,264,402 73,052,514 68,326,818 66,858,121 65,617,288 54,902,270 54,277,716 53,729,783 53,123,840 13,769 
        accumulated deficit
      		-1,005,871,000 -847,546,000 -689,884,000 -599,097,000 -533,536,000 -487,907,000 -452,490,000 -427,550,000 -405,299,000 -377,944,000 -353,339,000 -330,805,000 -311,580,000 -292,049,000 -272,490,000 -256,717,000 -239,285,000 -223,182,000 -210,826,000 -197,583,000 -182,202,000 -168,192,000 -157,244,000 -147,956,000 -138,384,000 -128,697,000 -121,247,000 -115,516,000 -107,842,000 -102,918,000 -97,678,000 -91,078,000 -84,406,000 -80,854,932 -76,770,459 -70,670,801 -65,499,167 -60,277,267 -56,632,658 -52,825,226 -49,132,433 -45,545,445 -40,454,482 -35,717,938 -27,852,872 
        accumulated other comprehensive loss
      		-856,000 378,000 374,000 -166,000 -216,000 -788,000 1,632,000 -2,272,000 -1,599,000 -389,000 -905,000 -1,040,000 -618,000  -1,761,000 -1,649,000 -1,411,000 -549,000 -170,000 -189,000 -104,000        -49,000 -423,000 -117,000 -147,000 -109,000 -19,769 -3,558 -5,999 -7,499 -6,892 -6,137 -6,786 -195 -7,370 -4,848 -12,461  
        total stockholders’ equity
      		501,917,000 639,062,000 713,030,000 795,461,000 846,918,000 880,278,000 911,448,000 920,980,000 933,892,000 348,419,000 368,240,000 386,115,000 134,065,000 145,322,000 151,285,000 165,230,000 182,270,000 201,884,000 213,121,000 224,974,000 237,223,000 244,344,000 253,793,000 261,947,000 268,283,000 277,119,000 283,492,000 288,354,000 294,574,000 297,750,000 302,053,000 140,363,000 72,632,000 13,464,836 2,225,961 6,587,879 7,546,087 8,042,867 10,219,525 12,785,469 5,769,739 8,724,998 13,270,551 17,393,539  
        total liabilities and stockholders’ equity
      		608,242,000 715,729,000 739,415,000 827,851,000 866,993,000 908,321,000 937,888,000 946,839,000 967,518,000 368,490,000 382,663,000 400,693,000 150,895,000 168,529,000 166,683,000 181,508,000 195,028,000 210,662,000 224,474,000 237,845,000 250,139,000 256,502,000 263,623,000 271,198,000 277,104,000 284,256,000 290,122,000 294,493,000 300,080,000 302,312,000 306,796,000 144,468,000 78,971,000 22,121,411 11,839,444 14,320,911 15,152,607 14,535,708 16,317,693 18,549,007 12,756,902 15,439,103 19,012,251   
        deferred financing costs
      		   8,000 32,000 56,000 80,000 105,000 98,000 106,000 130,000 16,000 48,000 38,000 15,000 52,000 64,000  88,000 7,000 27,000                         
        lease liability, net of current portion
      		  318,000 410,000 502,000 630,000 755,000 766,000 852,000 936,000 1,018,000 1,100,000 1,181,000 1,260,000 1,337,000 1,414,000 1,490,000     29,000 115,000 198,000 279,000 360,000 438,000 513,000 588,000                 
        total long-term liabilities
      		  318,000 410,000 502,000 630,000 755,000 766,000 852,000 936,000 1,018,000 1,100,000 1,181,000 1,260,000 1,337,000 1,414,000 1,490,000     29,000 115,000 198,000 279,000 360,000 438,000 513,000 588,000 12,000      6,054 4,224,354 16,307 20,476 24,646 5,069,038 4,737,293 19,149  2,899,669 
        preferred stock, 0.00001 par value: 10,000,000 shares authorized at december 31, 2025 and december 31, 2024; no shares issued and outstanding at december 31, 2025 and december 31, 2024
      		                                             
        treasury stock
      		         -6,795,000 -6,795,000 -6,795,000 -6,795,000 -6,795,000 -6,795,000 -6,795,000 -5,121,000                             
        preferred stock, 0.00001 par value: 10,000,000 shares authorized at september 30, 2025 and december 31, 2024; no shares issued and outstanding at september 30, 2025 and december 31, 2024
      		                                             
        preferred stock, 0.00001 par value: 10,000,000 shares authorized at june 30, 2025 and december 31, 2024; no shares issued and outstanding at june 30, 2025 and december 31, 2024
      		                                             
        preferred stock, 0.00001 par value: 10,000,000 shares authorized at march 31, 2025 and december 31, 2024; no shares issued and outstanding at march 31, 2025 and december 31, 2024
      		                                             
        preferred stock, 0.00001 par value: 10,000,000 shares authorized at december 31, 2024 and 2023; no shares issued and outstanding at december 31, 2024 and 2023
      		                                             
        preferred stock, 0.00001 par value: 10,000,000 shares authorized at september 30, 2024 and december 31, 2023; no shares issued and outstanding at september 30, 2024 and december 31, 2023
      		                                             
        preferred stock, 0.00001 par value: 10,000,000 shares authorized at june 30, 2024 and december 31, 2023; no shares issued and outstanding at june 30, 2024 and december 31, 2023
      		                                             
        preferred stock, 0.00001 par value: 10,000,000 shares authorized at march 31, 2024 and december 31, 2023; no shares issued and outstanding at march 31, 2024 and december 31, 2023
      		                                             
        preferred stock, 0.00001 par value: 10,000,000 shares authorized at december 31, 2023 and 2022; no shares issued and outstanding at december 31, 2023 and 2022
      		                                             
        preferred stock, 0.00001 par value: 10,000,000 shares authorized at september 30, 2023 and december 31, 2022; no shares issued and outstanding at september 30, 2023 and december 31, 2022
      		                                             
        preferred stock, 0.00001 par value: 10,000,000 shares authorized at june 30, 2023 and december 31, 2022; no shares issued and outstanding at june 30, 2023 and december 31, 2022
      		                                             
        preferred stock, 0.00001 par value: 10,000,000 shares authorized at march 31, 2023 and december 31, 2022; no shares issued and outstanding at march 31, 2023 and december 31, 2022
      		                                             
        short-term investments – available for sale
      		             118,853,000 125,615,000 152,691,000 172,445,000 175,732,000 204,871,000 219,429,000 224,874,000 219,269,000 251,434,000 244,212,000 253,901,000 267,261,000 257,120,000 273,513,000 284,375,000 276,741,000 134,656,000 107,556,000 41,112,000 11,587,478 7,270,719 8,689,630 7,954,240 10,075,058 11,562,950 12,036,539 7,292,863 13,335,499 15,349,507 12,162,251  
        preferred stock, 0.00001 par value: 10,000,000 shares authorized at december 31, 2022 and 2021; no shares issued and outstanding at december 31, 2022 and 2021
      		                                             
        accumulated other comprehensive income
      		             -1,102,000        -54,000 -46,000 333,000 -812,000 12,000 157,000 239,000                  
        preferred stock, 0.00001 par value: 10,000,000 shares authorized at september 30, 2022 and december 31, 2021; no shares issued and outstanding at september 30, 2022 and december 31, 2021
      		                                             
        preferred stock, 0.00001 par value: 10,000,000 shares authorized at june 30, 2022 and december 31, 2021; no shares issued and outstanding at june 30, 2022 and december 31, 2021
      		                                             
        preferred stock, 0.00001 par value: 10,000,000 shares authorized at march 31, 2022 and december 31, 2021; no shares issued and outstanding at march 31, 2022 and december 31, 2021
      		                                             
        deferred public offering and other financing costs
      		                 76,000    48,000 68,000 89,000 99,000 128,000 173,000 90,000 120,000 150,000 180,000 210,000 240,000 269,613 275,029 17,568 439,349 521,538 614,380       
        preferred stock, 0.00001 par value: 10,000,000 shares authorized at december 31, 2021 and 2020; no shares issued and outstanding at december 31, 2021 and 2020
      		                                             
        preferred stock, 0.00001 par value: 10,000,000 shares authorized at september 30, 2021 and december 31, 2020; no shares issued and outstanding at september 30, 2021 and december 31, 2020
      		                                             
        preferred stock, 0.00001 par value: 10,000,000 shares authorized at june 30, 2021 and december 31, 2020; no shares issued and outstanding at june 30, 2021 and december 31, 2020
      		                                             
        preferred stock, 0.00001 par value: 10,000,000 shares authorized at march 31, 2021 and december 31, 2020; no shares issued and outstanding at march 31, 2021 and december 31, 2020
      		                                             
        preferred stock, 0.00001 par value: 10,000,000 shares authorized at december 31, 2020 and 2019; no shares issued and outstanding at december 31, 2020 and 2019
      		                                             
        preferred stock, 0.00001 par value: 10,000,000 shares authorized at september 30, 2020 and december 31, 2019; no shares issued and outstanding at september 30, 2020 and december 31, 2019
      		                                             
        preferred stock, 0.00001 par value: 10,000,000 shares authorized at june 30, 2020 and december 31, 2019; no shares issued and outstanding at june 30, 2020 and december 31, 2019
      		                                             
        preferred stock, 0.00001 par value: 10,000,000 shares authorized at march 31, 2020 and december 31, 2019; no shares issued and outstanding at march 31, 2020 and december 31, 2019
      		                                             
        liabilities, convertible notes and stockholders’ equity
      		                                             
        deferred rent
      		                             12,000      6,054 10,862 16,307 20,476 24,646 27,624 31,239 19,149   
        preferred stock, 0.00001 par value: 10,000,000 shares authorized at december 31, 2019 and 2018; no shares issued and outstanding at december 31, 2019 and 2018
      		                                             
        preferred stock, 0.00001 par value: 10,000,000 shares authorized at september 30, 2019 and december 31, 2018; no shares issued and outstanding at september 30, 2019 and december 31, 2018
      		                                             
        preferred stock, 0.00001 par value: 10,000,000 shares authorized at june 30, 2019 and december 31, 2018; no shares issued and outstanding at june 30, 2019 and december 31, 2018
      		                                             
        preferred stock, 0.00001 par value: 10,000,000 shares authorized at march 31, 2019 and december 31, 2018; no shares issued and outstanding at march 31, 2019 and december 31, 2018
      		                                             
        accrued interest
      		                                 21,960    34,894     152,361 121,111 112,475 
        convertible notes payable, current portion
      		                                 3,450,540    3,269,582     1,911,024 1,670,509 310,350 
        debt conversion feature liability
      		                                 1,397,597   453,350 731,048   1,698,671  2,154,062 1,956,566 62,191 
        preferred stock, 0.00001 par value: 10,000,000 shares authorized at december 31, 2018 and 2017; no shares issued and outstanding at december 31, 2018 and 2017
      		                                             
        accrued interest, current
      		                                34,000  9,982 59,333   22,674 10,455      
        convertible notes payable, current
      		                                3,721,000  3,180,411 3,050,427   2,826,135 2,382,688      
        debt conversion feature liability, current
      		                                37,000  2,030,226 894,152   1,351,135 1,286,621      
        preferred stock, 0.00001 par value: 10,000,000 shares authorized at september 30, 2018 and december 31, 2017; no shares issued and outstanding at september 30, 2018 and december 31, 2017
      		                                             
        preferred stock, 0.00001 par value: 10,000,000 shares authorized at june 30, 2018 and december 31, 2017; no shares issued and outstanding at june 30, 2018 and december 31, 2017
      		                                             
        preferred stock, 0.00001 par value: 10,000,000 shares authorized at march 31, 2018 and december 31, 2017; no shares issued and outstanding at march 31, 2018 and december 31, 2017
      		                                             
        prepaid clinical trial costs
      		                                 886,873 1,346,171 1,732,789 2,183,180         
        preferred stock, 0.00001 par value: 10,000,000 shares authorized at december 31, 2017 and 2016; no shares issued and outstanding at december 31, 2017 and 2016
      		                                             
        preferred stock, 0.00001 par value: 10,000,000 shares authorized at september 30, 2017 and december 31, 2016; no shares issued and outstanding at september 30, 2017 and december 31, 2016
      		                                             
        preferred stock, 0.00001 par value: 10,000,000 shares authorized at june 30, 2017 and december 31, 2016; no shares issued and outstanding at june 30, 2017 and december 31, 2016
      		                                             
        accrued interest, non-current
      		                                    47,113    202,882 183,611    
        convertible notes payable
      		                                    3,713,029    3,139,861 2,151,540   1,429,993 
        preferred stock, 0.00001 par value: 10,000,000 shares authorized at march 31, 2017 and december 31, 2016; no shares issued and outstanding at march 31, 2017 and december 31, 2016
      		                                             
        preferred stock, 0.00001 par value: 10,000,000 shares authorized at december 31, 2016 and 2015; no shares issued and outstanding at december 31, 2016 and 2015
      		                                             
        preferred stock, 0.00001 par value: 10,000,000 shares authorized at september 30, 2016 and december 31, 2015; no shares issued and outstanding at september 30, 2016 and december 31, 2015
      		                                             
        deferred public offering financing costs
      		                                       158,842 515,381 157,455    
        preferred stock, 0.00001 par value: 10,000,000 shares authorized at june 30, 2016 and december 31, 2015; no shares issued and outstanding at june 30, 2016 and december 31, 2015
      		                                             
        preferred stock, 0.00001 par value: 10,000,000 shares authorized at march 31, 2016 and december 31, 2015; no shares issued and outstanding at march 31, 2016 and december 31, 2015
      		                                             
        accrued license fees
      		                                            24,826,374 
        stockholders’ equity
      		                                             
        preferred stock, 0.00001 par value: 10,000,000 shares authorized at december 31, 2015 and no shares authorized at december 31, 2014; no shares issued and outstanding at december 31, 2015 and 2014
      		                                             
        deferred ipo financing costs
      		                                            2,408,149 
        other assets
      		                                          80,000  775 
        total liabilities and stockholders’ deficit
      		                                           22,269,649 2,769,322 
        cash
      		                                            327,007 
        liabilities, convertible notes and stockholders’ deficit
      		                                             
        stockholders’ deficit:
      		                                             
        total stockholders’ deficit
      		                                            -27,839,043 
      Cashflow Statements:
      Quarterly
      Annual
        Unit: USD2026-03-31 2025-12-31 2025-09-30 2025-06-30 2025-03-31 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2020-06-30 2020-03-31 2019-12-31 2019-09-30 2019-06-30 2019-03-31 2018-12-31 2018-09-30 2018-06-30 2018-03-31 2017-12-31 2017-09-30 2017-06-30 2017-03-31 2016-12-31 2016-09-30 2016-06-30 2016-03-31 2015-12-31 2015-09-30 2015-06-30 2015-03-31 
                                                     
          cash flows from operating activities
        		                                             
          net loss
        		-158,325,000 -157,662,000 -90,787,000 -65,561,000 -45,629,000 -35,417,000 -24,940,000 -22,250,000 -27,356,000 -24,605,000 -22,534,000 -19,225,000 -19,531,000 -19,559,000 -15,773,000 -17,432,000 -16,103,000 -12,356,000 -13,243,000 -15,381,000 -14,010,000 -10,948,000 -9,288,000 -9,572,000 -9,687,000 -7,450,000 -5,731,000 -7,674,000 -4,924,000 -5,240,000 -6,600,000 -6,672,000 -3,551,000 -4,084,473 -6,099,658 -5,171,634 -5,221,900 -3,644,609 -3,807,432 -3,692,793 -3,586,988 -5,090,963 -4,736,544   
          adjustments to reconcile net loss to net cash from operating activities
        		                                             
          amortization of investment premiums
        		-1,293,000 -1,731,000 -2,029,000 -2,391,000 -3,133,000 -4,031,000 -4,979,000 -5,436,000 -2,821,000 -2,702,000 -3,145,000 -1,966,000 -389,000 -53,000 143,000 457,000 670,000 755,000 972,000       454,000    -71,000 -5,000 87,000 62,000 15,962 29,401 18,637 30,645 36,773 31,951 36,536 48,475 64,207 63,562   
          amortization of financing costs
        		 0 8,000 24,000 24,000 24,000 24,000 18,000 28,000 26,000 2,000 32,000 28,000 8,000 27,000 12,000 12,000 12,000 -35,000 20,000 21,000 21,000 20,000 20,000 45,000 46,000 40,000 30,000 30,000 30,000 30,000 30,000 30,000 33,516 17,568 421,781 98,179 92,849        
          stock-based compensation
        		10,337,000 8,587,000 7,336,000 13,547,000 11,348,000 5,667,000 8,982,000 7,082,000 7,981,000 4,080,000 4,481,000 4,620,000 3,569,000 2,156,000 1,940,000 2,220,000 2,357,000 1,433,000 1,599,000 1,491,000 1,577,000 1,042,000 1,475,000 1,649,000 1,652,000 976,000 811,000 922,000 1,034,000 617,000 750,000 631,000 610,000 363,840 344,128 341,258 402,239 358,575 320,953 490,245 624,554 527,444 601,592 1,471,509 903 
          amortization of right-of-use assets
        		85,000 94,000 114,000 112,000 111,000 110,000 87,000 75,000 74,000 74,000 73,000 73,000 72,000 72,000 142,000 0 77,000 76,000 75,000 73,000 72,000 71,000 70,000 68,000 68,000                     
          interest expense related to operating lease liability
        		1,000 -16,000 8,000 8,000 10,000 11,000 9,000 9,000 9,000 10,000 10,000 11,000 12,000 12,000 25,000 0 4,000 0 2,000 4,000 5,000 7,000 7,000 8,000 10,000                     
          changes in operating assets and liabilities:
        		                                             
          prepaid expenses and other current assets
        		4,628,000 14,278,000 -4,834,000 -5,089,000 -9,554,000 1,505,000 -2,728,000 -79,000 1,748,000 -58,000 1,373,000 7,351,000 -2,258,000 -1,432,000 823,000 -2,544,000 23,000 -307,000 1,254,000 -1,392,000 -266,000 112,000 -1,176,000 632,000 569,000 -6,670,000 -175,000 -610,000 75,000 1,686,000 -427,000 -1,080,000 -316,000 198,264 245,535 -167,483 221,310 181,200 108,227 -203,802 187,704 424,255 -912,432 -576,031 -15,564 
          accrued interest, net of interest receivable on maturity of investments
        		936,000 413,000 2,204,000 -11,000 2,470,000 -646,000 1,347,000 -157,000 655,000 -101,000 246,000                                   
          accounts payable
        		13,931,000 48,838,000 -1,081,000 -2,209,000 -2,110,000 9,561,000 -10,835,000 5,864,000 -2,287,000 1,801,000 100,000 1,813,000 -4,732,000 5,387,000 -2,963,000 2,954,000 1,707,000 -1,390,000 -1,377,000 -637,000 860,000 1,230,000 -452,000 127,000 650,000 343,000 219,000 194,000 716,000 -175,000 -330,000 829,000 -832,000 31,385 174,971 -465,782 522,935 376,825 -102,088 -47,253 449,701 81,951 92,849 7,131 37,306 
          accrued expenses
        		15,863,000 2,066,000 -4,802,000 14,643,000 -5,739,000 -7,836,000 11,280,000 -13,551,000 15,923,000 3,922,000 -177,000 -3,989,000 -1,572,000           -356,000 1,840,000 519,000 1,283,000 710,000 -118,000 337,000 1,015,000 544,000 -428,000 -477,484 318,488 696,814 472,143 281,704 252,381 77,300 -752,680 315,584 1,052,508 129,280 62,707 
          lease liability
        		-139,000 -116,000 -130,000 -130,000 -129,000 -128,000 -96,000 -90,000 -88,000 -87,000 -87,000 -88,000 -85,000 -84,000 -112,000 83,000 -76,000 -86,000 -85,000 -86,000 -85,000 -85,000 -83,000 -82,000 -83,000                     
          net cash from operating activities
        		-113,976,000 -85,290,000 -94,003,000 -47,061,000 -52,331,000 -31,181,000 -21,962,000 -28,513,000 -6,134,000 -17,640,000 -19,658,000 -11,435,000 -24,643,000 -10,926,000 -13,499,000 -13,442,000 -10,530,000 -12,350,000 -10,926,000 -13,434,000 -10,876,000 -5,486,000 -5,323,000 -6,666,000 -4,302,000 -11,743,000 -3,398,000 -6,459,000 -3,152,000 -2,679,000 -5,503,000 -5,270,000 -5,303,000 -3,948,002 -3,328,003 -4,203,170 -3,278,592 -2,464,884 -2,654,415 -3,226,840 -2,725,124 -3,299,390 -3,400,454 -1,620,709 -410,941 
          capital expenditures
        		0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
          free cash flows
        		-113,976,000 -85,290,000 -94,003,000 -47,061,000 -52,331,000 -31,181,000 -21,962,000 -28,513,000 -6,134,000 -17,640,000 -19,658,000 -11,435,000 -24,643,000 -10,926,000 -13,499,000 -13,442,000 -10,530,000 -12,350,000 -10,926,000 -13,434,000 -10,876,000 -5,486,000 -5,323,000 -6,666,000 -4,302,000 -11,743,000 -3,398,000 -6,459,000 -3,152,000 -2,679,000 -5,503,000 -5,270,000 -5,303,000 -3,948,002 -3,328,003 -4,203,170 -3,278,592 -2,464,884 -2,654,415 -3,226,840 -2,725,124 -3,299,390 -3,400,454 -1,620,709 -410,941 
          cash flows from investing activities
        		                                             
          purchases of investments
        		-72,437,000 -40,493,000 -21,454,000 -123,476,000 -232,614,000 -136,960,000 -149,985,000 -229,822,000 -596,601,000 -97,533,000 -79,399,000 -243,976,000 -57,395,000 -44,606,000 -10,445,000 -35,698,000 -30,682,000 -35,570,000 -24,167,000 -59,602,000 -48,676,000 -32,963,000 -108,682,000 -82,556,000 -56,435,000 -80,048,000 -99,474,000 -83,666,000 -99,218,000 -180,914,000 -53,583,000 -81,428,000 -32,279,000 -9,419,476 -2,680,171 -4,368,643 -6,057,417 -4,658,784 -2,016,972 -10,097,119 -149,360 0 -3,858,975   
          proceeds from maturities of investments
        		126,626,000   165,982,000 295,859,000  175,886,000 103,763,000 136,809,000      37,339,000 54,678,000 32,301,000  37,784,000 63,162,000 42,049,000  99,048,000 92,336,000 67,587,000  114,628,000 94,645,000 91,609,000  26,497,000 14,803,000 2,652,000             
          net cash from investing activities
        		54,189,000 75,612,000 160,025,000 42,506,000 63,245,000 6,584,000 25,901,000 -126,059,000 -459,792,000 35,733,000 -12,534,000 -204,483,000 2,198,000 7,260,000 26,894,000 18,980,000 1,619,000 27,410,000 13,617,000 3,560,000 -6,627,000 30,269,000 -9,634,000 9,780,000 11,152,000 -11,061,000 15,154,000 10,979,000 -7,609,000 -142,391,000 -27,086,000 -66,625,000 -29,627,000 -4,395,476 1,391,829 -764,643 2,038,583 1,447,216 441,028 -4,831,119 5,972,640 1,956,000 -3,251,975   
          cash flows from financing activities
        		                                             
          proceeds from exercises of stock options and other stock issuances
        		450,000  480,000 507,000 349,000                                         
          atm offering, net of fees
        		11,627,000     0 0 0 46,658,000 0 0 0 1,969,000                                 
          net cash from financing activities
        		12,077,000 75,103,000 480,000 507,000 349,000 1,000,000 2,522,000 2,905,000 606,037,000 188,000 -74,000 267,078,000 4,184,000 10,749,000 10,000 -1,590,000 -5,006,000 47,000 -256,000 1,898,000 5,191,000 464,000 37,000 416,000 33,000 229,000 73,000 260,000 325,000 343,000 167,485,000 70,149,000 62,298,000 14,763,893 1,110,586 4,002,418 2,523,553 1,038,278 108,349 9,259,126 -57,303 -28,175 -704,656 22,964,969 -17,909 
          net increase in cash and cash equivalents
        		-47,710,000 65,425,000 66,502,000 -4,048,000 11,263,000 -23,597,000 6,461,000 -151,667,000 140,111,000 18,281,000 -32,266,000   7,083,000    15,107,000 2,435,000 -7,976,000 -12,312,000 25,247,000 -14,920,000 3,530,000 6,883,000 -22,575,000 11,829,000 4,780,000 -10,436,000 -144,727,000 134,896,000 -1,746,000 27,368,000 6,420,415 -825,588 -965,395 1,283,544 20,610 -2,105,038 1,201,167 3,190,213 -1,371,565 -7,357,085   
          cash and cash equivalents beginning of period
        		165,810,000 0 0 0 26,676,000 0 0 0 55,516,000 0 0 0 36,632,000 0 0 0 26,371,000 0 0 0 29,117,000 0 0 0 8,377,000 0 0 0 24,779,000 0 0 0 8,988,000 0 0 0 3,075,502 0 0 0 768,550 0    
          effect of exchange rate changes on cash
        		16,000 9,000 -6,000 -12,000 1,000 -74,000 -29,000 3,000 -48,000 50,000 -68,000 -3,000 -9,000 141,000 -223,000                               
          cash and cash equivalents end of period
        		118,116,000 65,434,000 66,496,000 -4,060,000 37,940,000 -23,671,000 6,432,000 -151,664,000 195,579,000 18,331,000 -32,334,000 51,157,000 18,362,000 7,224,000 13,182,000 3,772,000 12,454,000 15,107,000 2,435,000 -7,976,000 16,805,000 25,247,000 -14,920,000 3,530,000 15,260,000 -22,575,000 11,829,000 4,780,000 14,343,000 -144,727,000 134,896,000 -1,746,000 36,356,000 6,420,415 -825,588 -965,395 4,359,046 20,610 -2,105,038 1,201,167 3,958,763 -1,371,565    
          supplemental disclosure of non-cash investing and financing transactions
        		                                             
          unpaid deferred public offering and other financing costs
        		50,000 0 0 0 50,000 0 -25,000 6,000 69,000 0 16,000 -18,000 52,000 6,000 -25,000 0 50,000 -19,000 19,000 0 50,000 0 0 -16,000 66,000 -8,000     -26,000 173,000 136,000 -79,924 71,705 131,749 16,055         
          realized gain on investment
        		     -1,000 -113,000                                       
          proceeds from sales and maturities of investments
        		 116,105,000        133,266,000 66,865,000 39,493,000 59,593,000                       3,604,000 8,096,000 6,106,000 2,458,000 5,266,000 6,122,000 1,956,000    
          public offering, net of offering costs
        		     0 0 -25,000 597,119,000 0 -73,000                                   
          value of shares withheld related to employee tax withholding
        		     0 0 0 -42,101,000 0 0 -5,407,000 -1,714,000 -1,034,000 0 0 -499,000 0 -234,000 0 -473,000 0 -169,000 0 -127,000 -27,000 -2,000 -38,000 -84,000 -26,000 -2,000   -7,628 -213   -5,210 -2,092   0 0   
          proceeds from warrant and option exercises and stock issuances under employee stock purchase plan
        		         188,000 -1,000 2,615,000 3,966,000 150,000 0 84,000 614,000  5,000 1,898,000 5,664,000  206,000 442,000 160,000                     
          right-of-use asset obtained in exchange for lease obligation
        		     0        0 0 0 1,664,000                             
          realized loss on investment
        		  -10,000            0                               
          repurchase of common stock
        		             0 0 -1,674,000 -5,121,000                             
          proceeds from option exercises and employee stock purchase plan common stock issuance
        		      2,522,000                                       
          proceeds from option exercises
        		        4,361,000                                     
          accrued interest, net of interest received on maturity of investments
        		            243,000 115,000 151,000 243,000 105,000 594,000 -11,000 759,000 -166,000 673,000                        
          public offering and financing costs
        		            -37,000     -19,000    0 0   -7,000    -283,000 -216,000 -120,000 -146,000 -376,272 -61,940 -46,055 -15,990 -71,624        
          net decrease in cash and cash equivalents
        		            -18,261,000   3,948,000 -13,917,000                             
          amortization of non-cash clinical trial costs
        		                         0 0 6,000 134,000 125,000 64,000 252,000 225,000 345,464 248,894 357,259 42,328         
          realized gain on investments
        		                     -26,000                        
          other accrued liabilities
        		              2,098,000 523,000 694,000  -77,000 674,000 -22,000                         
          public offering and finance costs
        		                                             
          receivable from exercise of warrants
        		                    173,000                         
          proceeds from stock issuance under employee stock purchase plan and warrant exercises
        		                                             
          amortization of investment premiums (accretion of investment discounts)
        		                    1,138,000  1,078,000 853,000 636,000   -37,000 -101,000                 
          realized loss on investments
        		                       -13,000 -2,000   0 2,000                 
          amortization of debt discount on notes payable
        		                             0 0 146,000 258,000 258,152 256,596 336,656 431,227 431,227 431,227 524,977 400,657 240,516 240,515   
          change in fair value of debt conversion feature liability
        		                             0 0 -37,000 -1,361,000 -632,628 1,136,074 -570,676 -277,698 -620,087 64,514 -412,050 -96,547 216,841 197,496 546,485 82,656 
          proceeds from issuances of common stock, net of underwriting discounts and commissions
        		                             0 165,205,000 72,580,000 58,822,000 14,519,612 1,250,000 4,042,735 2,539,543 1,103,996 525,772       
          repayment of convertible notes payable
        		                             0 0   0    0 0       
          supplemental disclosure of cash flow information:
        		                                             
          cash paid during the period for interest
        		                             0 0   0    0 0       
          proceeds from warrant and option exercises and stock issuance under employee stock purchase plan
        		                           298,000 409,000  2,498,000               
          deposits
        		                                             
          shares issued to cover future clinical trial costs
        		                                 0 0 0 1,800,000         
          shares issued as commitment fee in connection with lincoln park agreement
        		                                 0            
          proceeds from warrant and option exercises
        		                                3,622,000             
          repurchases of common stock
        		                                         0    
          shares issued as commitment fee in connection with aspire agreement
        		                                     0        
          shares issued in lieu of loan payment to related party
        		                                     0 0       
          proceeds from stock issuance under employee stock purchase plan
        		                                  0   11,345 0   20,489 0   
          change in fair value of accrued license fees
        		                                         0 0 4,421,337 4,960,511 
          shares issued in lieu of license fee payment
        		                                             
          conversion of notes payable
        		                                         0 0   
          issuance of common stock to consultant
        		                                         0 57,520   
          shares issued in lieu of license fee payment to related party
        		                                             
          public offering costs
        		                                       -551,947 -57,303 -48,664 -704,656   
          unpaid deferred public offering costs
        		                                       -27,423 409,414     
          accounts payable - related party
        		                                             
          accrued license fees
        		                                             
          proceeds from convertible notes payable
        		                                             
          issuance of common stock in exchange for notes receivable
        		                                             
          net proceeds from issuances of common stock
        		                                          0   
          shares issued in lieu of license fee
        		                                          58,495,422   
          unpaid deferred ipo costs
        		                                             
          cash, and cash equivalents beginning of period
        		                                             
          cash, and cash equivalents end of period
        		                                             
          net income
        		                                            -5,711,415 
          adjustments to reconcile net income to net cash from operating activities
        		                                             
          amortization of discount charged to interest expense on convertible notes
        		                                            171,955 
          deferred ipo financing costs paid
        		                                            -17,909 
          net increase in cash
        		                                            -428,850 
          cash, beginning of period
        		                                            755,857 
          cash, end of period
        		                                            327,007 
          deferred ipo costs included in accounts payable and accrued expenses
        		                                            2,057,903 
          •